Bristol Myers Squibb Company’s CAR-T therapy Breyanzi is set to enter the EU market for three lymphoma indications in advanced settings, with the firm touting outpatient administration as potentially boosting uptake in what has been a slow market.
Breyanzi (lisocabtagene maraleucel) received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for the...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

